10-May-2022 | Zion Market Research
The Brain Tumor Diagnosis and Treatment Market was worth around USD 1,395.7 million in 2021 and is estimated to grow to about USD 2,036.5 million by 2028, with a compound annual growth rate (CAGR) of approximately 6.5 percent over the forecast period. The report analyzes the Brain Tumor Diagnosis and Treatment Market drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the Brain Tumor Diagnosis and Treatment Market.
A brain tumor is an unregulated and abnormal proliferation of cells in the brain. It might be cancerous or benign. The brain tumor develops and seldom spreads from the brain tissue. The tumor eventually crushes and destroys other structures in the brain. Brain tumors are most commonly found in supportive brain structures. The precise etiology of a brain tumor is unknown, and it can occur at any age. The increased awareness among physicians and patients about the benefits of brain tumor detection and treatment will provide more attractive chances for market expansion. In addition, surging number of patients suffering from neurological disorders around the world, a rising number of smokers, an increasing prevalence of geriatric population, increasing government initiatives regarding growing awareness of advanced technologies, increasing demand for brain tumor diagnosis and treatment, and prevalence of favorable reimbursement policies are some of the major and vital factors that will likely augment the growth of brain tumor diagnosis and treatment. Moreover, the increasing number of technological advancements, as well as rising levels of investment in research and development activities, will further contribute by generating massive opportunities that will lead to the growth of the brain tumor diagnosis and treatment market during the forecasted timeframe. The high cost of therapy, combined with a lack of educated specialists, will most likely function as market barriers to the expansion of brain tumor diagnosis and treatment in the above-mentioned predicted timeframe. Product approval and commercialization issues will be the most difficult and time-consuming challenges to the market's growth.
The Brain Tumor Diagnosis and Treatment Market are segregated based on Diagnosis, Treatment, and Product Type. Based on Diagnosis, the global market is distinguished into MRI, CT Scan, PET-CT Scan, EEG, Molecular Testing, and Others. Based on Treatment, the global market is distinguished into Surgery, Radiation Therapy, Radiosurgery, Chemotherapy, Targeted Drug Therapy, and Immunotherapy. Based on Product Type, the global market is distinguished into Primary Brain Tumor and Secondary Brain Tumor.
North America dominates the brain tumor diagnostic and treatment market due to strong research and development efforts, a large number of people diagnosed with a brain tumor, and increased healthcare knowledge about brain tumor therapy and management. The developed healthcare industry in the United States, together with increased awareness of new technology among the populace in this region, is expected to propel the country to the top of the market. Meningioma is also the most prevalent type of brain tumor, followed by gliomas. In the United States, eflornithine is classified as an orphan medication and has been certified as a breakthrough therapy for the treatment of anaplastic glioma. This is projected to have a beneficial impact on market growth throughout the forecast period. Europe is predicted to develop at the fastest rate throughout the forecast period as a result of the government's initiative to raise awareness of new technology in the region. In addition, increased demand for oncology medications, rising brain cancer prevalence, and an aging population will drive the regional market.
Key players functioning in the Brain Tumor Diagnosis and Treatment Market include GE Healthcare, Merck & Co., Inc., AstraZeneca, Carestream Health, Philips Healthcare, Siemens Healthcare Private Limited, Shimadzu Corporation, Hitachi Medical Systems, Pfizer.Inc, and Toshiba Medical Systems.
Browse the full “Brain Tumor Diagnosis and Treatment Market By Diagnosis (MRI, CT Scan, PET-CT Scan, EEG, Molecular Testing, and Others). By Treatment (Surgery, Radiation Therapy, Radiosurgery, Chemotherapy, Targeted Drug Therapy, and Immunotherapy). By Product Type (Primary Brain Tumor and Secondary Brain Tumor).” Report at https://www.zionmarketresearch.com/report/brain-tumor-diagnosis-and-treatment-market
Brain Tumor Diagnosis and Treatment Market is segmented as follows:
By Diagnosis Type
By Treatment Type
By Product Type
Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.
Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651